Safety and Tolerability of Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry
Pediatric Cardiology · 10.08.2026
DOI: 10.1007/s00246-026-04409-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Cardiology, online erschienen am 10.08.2026. Verfasst von Neha Bansal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Cardiology, Hassenfeld Children's Hospital at NYU Langone Health, New York, NY, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, GlaxoSmithKline, Children's Cardiomyopathy Foundation.
Abstract (Originalsprache)
Long-term studies on safety of beta-blockers in pediatric heart failure (HF) are scant. We describe the safety profile, dose ranges, and tolerability of carvedilol in pediatric dilated cardiomyopathy (DCM). The Pediatric Cardiomyopathy Registry (PCMR) was used to identify patients with DCM, treated with carvedilol from 1997 to 2005. Descriptive statistics were analyzed and echocardiographic parameters were compared longitudinally using ANOVA. Total 118 patients were included with median age 4.4 years (interquartile range (IQR) 1.0–13.3). The etiology of DCM was idiopathic (66%), myocarditis (14%), familial DCM (21%). Majority (63%) had symptoms of HF at diagnosis and were on an angiotensin-converting enzyme inhibitor (ACEi) (95%) at carvedilol initiation. The mean ± standard deviation (SD) carvedilol dose at 1 year was 0.38 ± 0.44 mg/kg/dose. The median duration of carvedilol therapy studied was 361 days (IQR 101–958) with 18% of the patients treated for > 3 years. Few patients (< 10%) had blood pressure or heart rate below safety thresholds with no admission for hypotension or bradycardia. Only 4 patients discontinued carvedilol for bradycardia (n = 1), fatigue (n = 1), poor LV function (n = 1) and worsening renal function (n = 1). Mean left ventricular shortening fraction (LVFS) was 16% ± 8 at carvedilol initiation (n = 98), 21% ± 9 at 1 year (n = 49) and 23% ± 9 at 2 years (n = 20) post-carvedilol initiation, suggesting a possible clinical benefit (p < 0.01). These results provide safety data for chronic carvedilol use in children and show a low prevalence of discontinuation for adverse events. Further study of the long-term remodeling effects of chronic beta-blocker use in pediatric HF is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Cardiology, Hassenfeld Children's Hospital at NYU Langone Health, New York, NY, USA.
- Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- University of Massachusetts, Boston, Boston, MA, USA.
- Children's Hospital at Montefiore, Bronx, NY, USA.
- St. Louis Children's Hospital, St. Louis, MO, USA.
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Förderung
- NHLBI NIH HHS
- GlaxoSmithKline
- Children's Cardiomyopathy Foundation
- Kyle John Rymiszewski Foundation
- National Heart, Lung, and Blood Institute
Zitieren
APA
Bansal, N., Rossano, J. W., Shi, L., Hsu, D. T., Canter, C. E., Pahl, E., Towbin, J. A., Colan, S. D., Kantor, P. F., Everitt, M. D., Ballweg, J. A., Simpson, K. E., & Lipshultz, S. E. (2026). Safety and Tolerability of Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry. Pediatric Cardiology. https://doi.org/10.1007/s00246-026-04409-7
Vancouver
Bansal N, Rossano JW, Shi L, Hsu DT, Canter CE, Pahl E, et al. Safety and Tolerability of Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry. Pediatric Cardiology. 2026. doi:10.1007/s00246-026-04409-7
BibTeX
@article{Bansal2026,
author = {Bansal, Neha and Rossano, Joseph W and Shi, Ling and Hsu, Daphne T and Canter, Charles E and Pahl, Elfriede and Towbin, Jeffrey A and Colan, Steven D and Kantor, Paul F and Everitt, Melanie D and Ballweg, Jean A and Simpson, Kathleen E and Lipshultz, Steven E},
title = {Safety and Tolerability of Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry},
journal = {Pediatric Cardiology},
year = {2026},
doi = {10.1007/s00246-026-04409-7}
}
EUVIMED